Research programme: gonorrhoea therapeutics- Collaborations Pharmaceuticals
Latest Information Update: 28 Aug 2023
At a glance
- Originator Collaborations Pharmaceuticals
- Class Antibacterials; Small molecules
- Mechanism of Action Bacterial growth inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Gonorrhoea
Most Recent Events
- 04 Jul 2023 Early research in Gonorrhoea in USA prior to July 2023 (Collaborations Pharmaceuticals pipeline, July 2023)
- 04 Jul 2023 Neisseria gonorrhoeae therpeutic- Collaborations Pharmaceuticals is available for licensing as of 04 Jul 2023. https://www.collaborationspharma.com/partnerships (Collaboration Pharmaceuticals website, August 2023).
- 04 Jul 2023 Preclinical trials in Gonorrhoea in USA (unspecified route) (Collaborations Pharmaceuticals pipeline, July 2023)